The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So what it was found that in the people with type 2 diabetes, that fat is not active. And in fact, it can produce ceramides and other pre-inflammatory mediators that are not only involved with insulin resistance, but maybe with cardiovascular disease or atherosclerosis. they cannot be oxidized in the mitochondria. So they build up outside.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
whereas in in this in this population it continues to grow my colleague Brian Bergman from the university is working a lot um into the content of what's inside this these flat droplets but one thing that we know is like they're very high in ceramides and diglycerites and especially ceramides are key in the atherosclerotic process
whereas in in uh um people with type two diabetes or obesity it's it's it's stagnant it keeps growing and and it releases pre-inflammatory mediators and it also is high in ceramides which are key in AOS sclerosis